STOCK TITAN
  1. Home
  2. News
  3. NYMX

Nymox Pharmaceutical Corp - NYMX STOCK NEWS

Welcome to our dedicated news page for Nymox Pharmaceutical (Ticker: NYMX), a resource for investors and traders seeking the latest updates and insights on Nymox Pharmaceutical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nymox Pharmaceutical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nymox Pharmaceutical's position in the market.

News
Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
Rhea-AI Summary
Nymox Pharmaceutical Corporation announces long-term clinical trial results for NYMOZARFEX(TM) in the treatment of low grade localized prostate cancer. The study shows a significant reduction in the need for prostate cancer surgery, radiotherapy, and chemotherapy. The treatment was administered via a painless injection directly into the prostate and demonstrated persistent long-term benefit with minimal side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.91%
Tags
clinical trial
-
News
Nymox Reports on U.S. Patent Issuances
Rhea-AI Summary
Nymox Pharmaceutical Corporation announces the issuance of important U.S. patents for NYMOZARFEX, expanding its patent portfolio. The patents cover treatments for prostate enlargement (BPH) and prostate cancer. CEO Paul Averback is the inventor behind the technology and patents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.33%
Tags
none
-
News
Nymox Update
Rhea-AI Summary
Nymox Pharmaceutical Corporation provides additional information regarding recent changes in the board of directors and management. The company terminated the employment of its former in-house legal counsel and chief financial officer. They also rejected a potential transaction due to several reasons, including the excessive awards of up to 18 million shares of common stock to the former CFO and legal counsel, as well as the potential business partner not paying cash for certain rights but creating a debt on the company's balance sheet. The former CFO and legal counsel failed to disclose their roles in an unrelated company and sought financing from Nymox shareholders without disclosure. Nymox is focused on submitting applications for the approval of its drug NYMOZARFEX to treat benign prostatic hyperplasia (BPH), a common condition in middle-aged and elderly men with limited treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
News
Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
management
-
News
NYMOX Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Nymox Delisting from NASDAQ
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.68%
Tags
none
News
Nymox Provides Current Update
Rhea-AI Summary
Nymox Pharmaceutical Corporation provides a mid-2nd quarter update on ongoing activities. The company expects to submit a new submission for marketing approval of Nymozarfex, its molecular treatment for benign prostate enlargement (BPH). Nymozarfex is a painless long-lasting treatment with no adverse effects, given once in a convenient office administration. The company has gained new patent approvals worldwide. BPH affects a large percentage of the male population and surgery is often needed. The company has submitted its application for Marketing Authorization Application to the Danish authorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
News
Nymox Provides Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none
-
News
Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
management
News
Nymox Officially Granted Extension to Regain Listing Requirements
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.53%
Tags
none
Stock NYMX logo
Nymox Pharmaceutical Corp

OTC:NYMX

NYMX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NYMX Stock Data

18.25M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About NYMX

nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.